BCM
TEVA icon

Brookstone Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Brookstone Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-432
Closed -$24K – 806
2015
Q3 		$24K Sell
432
-100
-19% -$6.48K ﹤0.01% 705
2015
Q2 		$31K Buy
+532
New +$32.8K ﹤0.01% 653

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Brookstone Capital Management's TEVA Position: Q4 2015 in Review

Brookstone Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 432 shares — an estimated $24K sold.

Brookstone Capital Management first reported a position in TEVA in Q2 2015 and held it in 2 quarters. The position peaked at $31K in Q2 2015. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

  • Brookstone Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Brookstone Capital Management sold 432 Teva Pharmaceuticals shares in Q4 2015, an estimated $24K.
  • Brookstone Capital Management first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Brookstone Capital Management's Teva Pharmaceuticals position peaked at $31K in Q2 2015.
  • 876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on Brookstone Capital Management's 13F filing for Q4 2015, filed 14 Jan 2016.